PD-1/L1 inhibitors have demonstrated significant efficacy in some patients with advanced GC by blocking the interaction between PD-1 and PD-L1, thereby reactivating the anti-tumor activity of T cells and enhancing the immune response of the body. This evidence concerns the gene PDCD1 and neoplasm.